Piperacillin / Tazobactam

Piperacillin/tazobactam injection is approved to treat several types of serious bacterial infections. Uses in pediatric patients (2 months of age and older) are for intra-abdominal infections and nosocomial pneumonia only; additional uses in adults are listed below.

• Intra-abdominal infections (adults and children 2 months+): complicated appendicitis (including rupture or abscess) and peritonitis
• Nosocomial pneumonia (adults and children 2 months+): moderate-to-severe pneumonia acquired in a hospital setting; Pseudomonas aeruginosa cases require combination with an aminoglycoside antibiotic
• Skin and skin structure infections (adults only): including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections
• Female pelvic infections (adults only): postpartum endometritis and pelvic inflammatory disease
• Community-acquired pneumonia (adults only): moderate severity only, caused by susceptible Haemophilus influenzae
• Used only for infections proven or strongly suspected to be caused by bacteria, to preserve antibiotic effectiveness

Piperacillin is a penicillin-class antibiotic that kills bacteria by interfering with the construction of their cell walls. Without an intact cell wall, bacteria cannot survive. Tazobactam does not kill bacteria on its own, but it plays a critical supporting role: it blocks beta-lactamase enzymes — proteins that some bacteria produce specifically to destroy penicillin antibiotics. By shutting down those enzymes, tazobactam keeps piperacillin effective against a wider range of bacteria.

Importantly, tazobactam does not trigger bacteria to produce more of these resistance enzymes at the doses used clinically, which helps preserve its protective effect during treatment.

Piperacillin/tazobactam is given only by intravenous (IV) infusion in a hospital or clinical setting — it is not taken by mouth. Each dose is infused slowly over 30 minutes. Adults typically receive doses every 6 hours; pediatric dosing frequency varies by age and condition (every 6 or every 8 hours). Patients with reduced kidney function or those on dialysis require lower doses, adjusted based on how well the kidneys are working. Always follow your prescriber's exact instructions.

• Given by IV infusion only — not available as an oral medication
• Each infusion takes 30 minutes
• Dose frequency is every 6 hours for most adult indications; pediatric frequency depends on age and the condition being treated
• Kidney function affects dosing — tell your care team about any kidney problems

The most common side effects of piperacillin/tazobactam include:

• Diarrhea (very common)
• Constipation
• Nausea and vomiting
• Headache
• Trouble sleeping (insomnia)
• Skin rash or itching
• Fever
• Oral or systemic candidiasis (yeast infection)

Seek medical attention immediately for severe or worsening rash, difficulty breathing, chest tightness, signs of an allergic reaction, unusual muscle pain or dark urine, seizures, or severe persistent diarrhea — these can signal serious reactions that require prompt treatment.

• Serious allergic reactions: Life-threatening anaphylaxis (a severe allergic response causing shock) has been reported. Anyone allergic to penicillins, cephalosporins, or beta-lactamase inhibitors must not receive this medication.
• Severe skin reactions: Rare but dangerous skin conditions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, AGEP) can occur. Worsening or blistering rash requires immediate medical evaluation.
• Kidney toxicity in critically ill patients: Piperacillin/tazobactam was found to be an independent risk factor for kidney failure in critically ill patients. When used with vancomycin, the risk of acute kidney injury increases further. Alternative antibiotics should be considered for critically ill patients when possible.
• Hemophagocytic lymphohistiocytosis (HLH): A rare but serious immune system reaction has been reported. Signs include fever, rash, swollen lymph nodes, and enlarged liver or spleen. Stop the medication immediately if HLH is suspected.
• Rhabdomyolysis: Breakdown of muscle tissue has been reported. Muscle pain or weakness, tenderness, or dark urine should prompt immediate medical evaluation.
• Seizures and neuromuscular effects: Higher doses and kidney impairment increase the risk of seizures. Patients with seizure disorders need close monitoring.
• C. difficile-associated diarrhea: Like all antibiotics, this drug can disrupt normal gut bacteria and allow C. difficile to overgrow, causing diarrhea that can range from mild to life-threatening colitis.
• Blood count changes: Prolonged use can reduce white blood cell and platelet counts. Blood tests should be monitored during extended courses of therapy (21 days or more).

Piperacillin/tazobactam can interact with several medications, affecting either its effectiveness or the safety of the other drug:

• Aminoglycoside antibiotics (tobramycin, gentamicin, amikacin): Piperacillin can chemically inactivate aminoglycosides if mixed together. They must always be administered separately. In dialysis patients, tobramycin blood levels can drop significantly and must be monitored.
• Vancomycin: Combining these two antibiotics increases the risk of acute kidney injury. Kidney function should be closely monitored.
• Probenecid: This gout medication slows the body's removal of piperacillin and tazobactam, raising their blood levels. Co-administration should be avoided unless clearly necessary.
• Blood thinners (heparin, warfarin, and other anticoagulants): Piperacillin/tazobactam can affect clotting, so clotting tests need to be checked more frequently.
• Vecuronium and other neuromuscular blocking agents: Piperacillin/tazobactam can prolong the muscle-relaxing effects of these drugs used during surgery or procedures.
• Methotrexate: Piperacillin may reduce the kidney's ability to clear methotrexate, increasing the risk of methotrexate toxicity. Frequent monitoring of methotrexate levels is needed.
• Aspergillus blood tests: This medication can cause false-positive results on certain fungal infection tests (Bio-Rad Platelia Aspergillus EIA). Positive results should be confirmed by other methods.
• Urine glucose tests: Piperacillin/tazobactam can cause a false-positive result on copper-reduction urine glucose tests (such as Clinitest). Enzyme-based glucose tests should be used instead.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Penicillin/antibiotic allergy: Do not use if you have ever had an allergic reaction to penicillins, cephalosporins, or beta-lactamase inhibitors — this is a contraindication.
• Kidney impairment: Doses must be reduced if creatinine clearance is 40 mL/min or below; dialysis patients also require adjusted dosing.
• Seizure disorders: Tell your doctor — the risk of seizures may be higher, especially at higher doses or with impaired kidneys.
• Critically ill patients: There is a higher risk of kidney failure in this population; your care team should weigh whether an alternative antibiotic is more appropriate.
• Cystic fibrosis: A higher rate of fever and rash has been observed with piperacillin-type antibiotics in cystic fibrosis patients.
• Pregnancy: Piperacillin/tazobactam crosses the placenta. There is not enough human data to fully assess the risk; discuss with your doctor.
• Breastfeeding: Piperacillin is excreted in breast milk. The effect on a nursing infant is not fully known. Discuss with your doctor to weigh benefits and risks.
• Children under 2 months: Safety and effectiveness have not been established in infants younger than 2 months.
• Older adults: Age alone does not increase risk, but older adults are more likely to have reduced kidney function, requiring careful dose selection and kidney monitoring.
• Restricted sodium diet: This medication contains sodium — a consideration for patients who need to limit salt intake, including those with heart conditions.
• Low potassium levels: Patients on diuretics or chemotherapy with potentially low potassium should have their electrolytes checked during treatment.

If too much piperacillin/tazobactam is given, the most likely symptoms are nausea, vomiting, and diarrhea — similar to normal side effects but more intense. At very high levels, particularly in people with kidney problems, it can cause neuromuscular excitability (unusual muscle twitching or jerking) or seizures. Treatment focuses on supportive care based on the person's symptoms. Hemodialysis can remove a meaningful portion of both piperacillin and tazobactam from the blood if needed.

The key measure of how well piperacillin/tazobactam works is the amount of time its concentration in the blood stays above the minimum level needed to inhibit bacterial growth — called the time above MIC (minimum inhibitory concentration). Keeping drug levels above this threshold for enough time during each dosing interval is what drives bacterial killing and clinical success. This is why dosing frequency and infusion timing matter so much with this antibiotic.

After a 30-minute IV infusion, peak blood levels of piperacillin and tazobactam are reached immediately at the end of the infusion. Both drugs have short half-lives of roughly 0.7 to 1.2 hours, meaning the body clears them relatively quickly. They spread widely into body tissues — including the lungs, intestines, gallbladder, skin, and female reproductive organs — reaching tissue levels generally 50–100% of blood levels. Both piperacillin and tazobactam are eliminated primarily by the kidneys; in people with reduced kidney function, both drugs clear more slowly and levels build up, which is why dose adjustments are essential. Hemodialysis removes approximately 30–40% of a piperacillin/tazobactam dose.

Prior to Reconstitution: Store at 20° to 25°C (68° to 77°F).